Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) Receives Average Rating of “Moderate Buy” from Analysts

Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) has received an average recommendation of “Moderate Buy” from the five research firms that are presently covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell rating and four have issued a buy rating on the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $8.3333.

A number of analysts recently commented on AUTL shares. Needham & Company LLC decreased their target price on Autolus Therapeutics from $11.00 to $10.00 and set a “buy” rating for the company in a research report on Monday, January 12th. William Blair restated an “outperform” rating on shares of Autolus Therapeutics in a report on Wednesday, September 24th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Autolus Therapeutics in a report on Wednesday, October 8th. Finally, Wall Street Zen lowered shares of Autolus Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Saturday, November 15th.

Autolus Therapeutics Stock Down 4.2%

NASDAQ:AUTL opened at $1.38 on Tuesday. The firm has a market capitalization of $367.28 million, a P/E ratio of -1.66 and a beta of 2.01. Autolus Therapeutics has a twelve month low of $1.11 and a twelve month high of $2.70. The company has a fifty day moving average of $1.56 and a 200-day moving average of $1.74.

Autolus Therapeutics (NASDAQ:AUTL) last posted its quarterly earnings results on Wednesday, November 12th. The company reported ($0.30) EPS for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.07). Autolus Therapeutics had a negative return on equity of 63.76% and a negative net margin of 439.69%.The company had revenue of $21.19 million during the quarter, compared to analyst estimates of $21.08 million. On average, analysts anticipate that Autolus Therapeutics will post -0.94 EPS for the current fiscal year.

Institutional Investors Weigh In On Autolus Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the business. Marex Group plc bought a new position in Autolus Therapeutics in the 2nd quarter valued at about $28,000. Caitong International Asset Management Co. Ltd purchased a new position in shares of Autolus Therapeutics during the third quarter valued at approximately $46,000. R Squared Ltd purchased a new position in shares of Autolus Therapeutics during the second quarter valued at approximately $50,000. Invesco Ltd. grew its holdings in Autolus Therapeutics by 53.3% during the first quarter. Invesco Ltd. now owns 32,738 shares of the company’s stock worth $51,000 after buying an additional 11,381 shares in the last quarter. Finally, Delaney Dennis R purchased a new stake in Autolus Therapeutics in the 2nd quarter valued at $55,000. Institutional investors and hedge funds own 72.83% of the company’s stock.

Autolus Therapeutics Company Profile

Autolus Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of next-generation, programmed T cell therapies for the treatment of cancer. The company leverages proprietary technologies to engineer autologous T cells that target and eradicate tumor cells, with the aim of improving safety, efficacy and durability over existing cell therapies. Its R&D platform integrates antigen receptor design, gene editing and manufacturing optimization to generate candidates tailored for specific hematologic malignancies and solid tumor indications.

The company’s leading pipeline candidates include AUTO1, an optimized CD19-targeted CAR-T therapy for relapsed or refractory acute lymphoblastic leukemia, and AUTO3, a dual-targeted CD19/22 CAR-T program in development for diffuse large B-cell lymphoma.